

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

10/601,312 06/23/2003 Yair Assaf 25523 755 20529 7590 06/15/2005 EXAMINER NATH & ASSOCIATES 1030 15th STREET, NW 6TH FLOOR ART UNIT PAPER N				1	- 1	1	ΓЕ	3 DATE	ING D	ILIN	FILI	FIL	FI	l		1	- 1	Ю.	יא אכ	CATIO	PLIC	LICA	ICATIO
NATH & ASSOCIATES 1030 15th STREET, NW	•)3	/2003	5/23/2	06/2	06	00	(312	/601,3	10/0	10/60	0/601,
1030 15th STREET, NW					5	.005	/1 <i>5/</i> 200	06/1	(0	7590	759			529	205	20529	0529
' ADTIDIT DADED N								S															
VIIITLOOK									•	* **	14 41	141	, 14	1,1	1 1	CLL							
WASHINGTON, DC 20005 3763	WASHINGTON, DC 20005																						

DATE MAILED: 06/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Commons	10/601,312	ASSAF, YAIR
Office Action Summary	Examiner	Art Unit
	Manuel Mendez	3763
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply if NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	ely filed s will be considered timely, the mailing date of this communication, D (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 24 Ma	arch 2005.	
2a) ☐ This action is FINAL . 2b) ☑ This	action is non-final.	
3) Since this application is in condition for allowan		
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.
Disposition of Claims	•	
4)⊠ Claim(s) <u>1-38</u> is/are pending in the application.	•	
4a) Of the above claim(s) 23-38 is/are withdraw	n from consideration.	
5) Claim(s) is/are allowed.	•	
6)⊠ Claim(s) <u>1-22</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/or	election requirement.	
Application Papers		
9) The specification is objected to by the Examiner	·	
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by the E	Examiner.
Applicant may not request that any objection to the o	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).
1. Certified copies of the priority documents	s have been received.	
2. Certified copies of the priority documents		
3. Copies of the certified copies of the prior	•	ed in this National Stage
application from the International Bureau	·	d
* See the attached detailed Office action for a list of	or the certified copies not receive	u.
Attachment(s)		1 /
1) Notice of References Cited (PTO-892)	4) Interview Summary	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ite atent Application (PTO-152)
3). Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	atent Application (FTO-102)
S. Patent and Trademark Office		

Art Unit: 3763

DETAILED ACTION

Election/Restrictions

Claims 23-38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 03/24/2005.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Art Unit: 3763

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by **Heath, U.S.**Patent No. 5,725,570 and **Heath, U.S.** Patent No. 6,287,331. The cited patents teach the use of metal coatings greater than 12 g/cc in order to increase visibility.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 14 is rejected under 35 U.S.C. 103(a) as being unpatentable over Sarkis et al., in view of Thomas.

The Sarkis et al., patent teaches the use of medical devices with Echogenic coatings for the infusion of agents into the body. Sarkis et al., does not expressly disclose the use of medical infusion devices for the infusion of blood clotting agents. However, the use of infusion devices for the infusion of blood clotting agents in the treatment of aneurysms is conventional in the art as evidenced by the teachings of Thomas. The Thomas patent teaches the use of syringes, needles, and other medical instruments for the infusion of agents during vasoconstriction procedures. Accordingly, for a person of ordinary skill in the art, using the infusion devices disclosed by Sarkis et al., for the infusion of blood clotting agents would have been considered an obvious in view of the conventionality of said use.

Claims 2-13 and 15-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sarkis et al., in view of Thomas, as disclosed above, and in

Art Unit: 3763

further view of Heath, U.S. Patent No. 5,725,570 and Heath, U.S. Patent No. 6,287,331.

Sarkis et al., does not disclose the use of metal coatings having specific densities such as 12 g/cc and 15 g/cc. However, the use of metal coatings in infusion devices is conventional in the art as evidenced by the teachings Heath, U.S. Patent No. 5,725,570 and Heath, U.S. Patent No. 6,287,331. Accordingly, for a person of ordinary skill in the art, enhancing the infusion devices disclosed in the Sarkis et al., patent with metal coatings having densities greater than 12 g/cc and 15 g/cc would have been considered obvious in view of the conventionality of these enhancements.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manuel Mendez whose telephone number is 703-308-2221. The examiner can normally be reached on 0730-1800 hrs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 5

Manuel Mendez
Primary Examiner
Art Unit 3763

MM